Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Panelists discuss how a woman aged 55 years with T3N1M0 locally advanced squamous cell carcinoma represents a typical case for definitive chemoradiation therapy over surgical resection, emphasizing ...

Are you at risk of cancer due to certain chemicals, ingredients or procedures used in skin enhancement treatments? Here's what an oncologist wants you to know.

Every day, some 9,500 Americans learn they have skin cancer - yet there are some easy steps you can take to lower your risk.

Skin cancer is the most common type of cancer in the U.S., and it has increased dramatically in the last 50 years. Melanoma, ...

Talking to loved ones about a recent head and neck cancer diagnosis can be overwhelming. Of course, there is no one "right" ...

Oral squamous cell carcinoma (OSCC) is the most common cancer in the oral and maxillofacial region. Due to the special physiological and anatomical position of the oral cavity, the disease often has a ...

NASCAR is partnering with Regeneron to educate people on the two most common forms of advanced non-melanoma skin cancer.

Each year in the U.S., an estimated 6.1 million people are treated for skin cancer, and that number is growing.

And while exposure to UV light was historically used as a medical treatment until the 1940s, doctors abandoned it when ...

Medicus Pharma offers high-risk, high-reward potential, with its novel SkinJect patch for basal cell carcinoma and Antev ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...